| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kolasa Magdalena, Nikiforuk Agnieszka, Korlatowicz Agata, Solich Joanna, Potasiewicz Agnieszka, Marta Dziedzicka-Wasylewska, Bugno Ryszard, Hogendorf Adam, Bojarski Andrzej, Faron-Górecka Agat. Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. Psychopharmacology. 2024-07-04. PMID:38963553. |
our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of psilocybin (psi) in treating treatment-resistant depression (trd). |
2024-07-04 |
2024-07-10 |
rat |
| Joshua M Poulin, Gregory E Bigford, Krista L Lanctôt, Peter Giacobbe, Ayal Schaffer, Mark Sinyor, Jennifer S Rabin, Mario Masellis, Amit Singnurkar, Christopher B Pople, Nir Lipsman, Muhammad I Husain, Joshua D Rosenblat, Xingshan Cao, Bradley J MacIntosh, Sean M Nesto. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression. Trials. vol 25. issue 1. 2024-07-03. PMID:38956594. |
engaging mood brain circuits with psilocybin (embrace): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression. |
2024-07-03 |
2024-07-06 |
Not clear |
| Joshua M Poulin, Gregory E Bigford, Krista L Lanctôt, Peter Giacobbe, Ayal Schaffer, Mark Sinyor, Jennifer S Rabin, Mario Masellis, Amit Singnurkar, Christopher B Pople, Nir Lipsman, Muhammad I Husain, Joshua D Rosenblat, Xingshan Cao, Bradley J MacIntosh, Sean M Nesto. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression. Trials. vol 25. issue 1. 2024-07-03. PMID:38956594. |
we aim to examine for the first time how psilocybin acutely (intraday) and subacutely (weeks) alters functional brain networks implicated in depression. |
2024-07-03 |
2024-07-06 |
Not clear |
| Daisuke Ib. [Up-to-Date on clinical and preclinical studies of psilocybin therapy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. vol 159. issue 4. 2024-06-30. PMID:38945903. |
in 2016, carhart-harris and colleagues reported that psilocybin, the hallucinogenic compound derived from magic mushrooms, exhibits rapid and enduring antidepressant effects in patients with treatment-resistant depression. |
2024-06-30 |
2024-07-03 |
Not clear |
| Daisuke Ib. [Up-to-Date on clinical and preclinical studies of psilocybin therapy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. vol 159. issue 4. 2024-06-30. PMID:38945903. |
in 2018 and 2019, the u.s. food and drug administration designated psilocybin as a "breakthrough medicine" for treatment-resistant depression and mdd, respectively. |
2024-06-30 |
2024-07-03 |
Not clear |
| David S Jacobs, Alina P Bogachuk, Chloé L Le Moing, Bita Moghadda. Effects of psilocybin on uncertain punishment learning. Neurobiology of learning and memory. 2024-06-23. PMID:38909970. |
psilocybin may provide a useful treatment for mood disorders including anxiety and depression but its mechanisms of action for these effects are not well understood. |
2024-06-23 |
2024-06-26 |
rat |
| Catherine K Wang, Gio Kim, Lily R Aleksandrova, William J Panenka, Alasdair M Bar. A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity. Frontiers in pharmacology. vol 15. 2024-06-19. PMID:38887548. |
one of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such as psilocybin for treatment-resistant depression. |
2024-06-19 |
2024-06-21 |
Not clear |
| FranciscoJ Appiani, Stanley N Carof. The cyclical revival of psychedelics in psychiatric treatment. Current medical research and opinion. 2024-06-16. PMID:38880945. |
over recent years, a surge of interest has focused on exploring the safety and efficacy of psilocybin as a potential treatment for depression. |
2024-06-16 |
2024-06-19 |
Not clear |
| Noah Chisamore, Danica Johnson, Margery J Q Chen, Hilary Offman, David Chen-Li, Erica S Kaczmarek, Zoe Doyle, Roger S McIntyre, Joshua D Rosenbla. Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review. Journal of psychiatric research. vol 176. 2024-06-08. PMID:38850581. |
protocols and practices in psilocybin assisted psychotherapy for depression: a systematic review. |
2024-06-08 |
2024-06-11 |
Not clear |
| Mengyang Xu, Andor J Kiss, J Andrew Jones, Matthew S McMurray, Haifei Sh. Effect of oral tryptamines on the gut microbiome of rats-a preliminary study. PeerJ. vol 12. 2024-06-07. PMID:38846751. |
psilocybin and related tryptamines have come into the spotlight in recent years as potential therapeutics for depression. |
2024-06-07 |
2024-06-10 |
Not clear |
| Laura Ramos, Selene G Vicent. The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. Journal of clinical and experimental neuropsychology. 2024-06-06. PMID:38842300. |
the effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. |
2024-06-06 |
2024-06-08 |
Not clear |
| Laura Ramos, Selene G Vicent. The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. Journal of clinical and experimental neuropsychology. 2024-06-06. PMID:38842300. |
studying psilocybin effects on cognition and emotional processing may help to clarify the mechanisms underlying the therapeutic potential of psilocybin and may also support studies with people suffering from depression. |
2024-06-06 |
2024-06-08 |
Not clear |
| Qiwen Fang, Vivien Kin Yi Chan, Sandra Sau Man Chan, Yuanshi Jiao, Jiaqi Wang, Xue L. Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis. Psychiatry research. vol 337. 2024-05-23. PMID:38781672. |
efficacy and safety of psilocybin on treatment-resistant depression: a systematic review and meta-analysis. |
2024-05-23 |
2024-05-27 |
Not clear |
| David Nutt, Ilana Crome, Allan H Youn. Is it now time to prepare psychiatry for a psychedelic future? The British journal of psychiatry : the journal of mental science. 2024-05-19. PMID:38764044. |
australia has just rescheduled two drugs controlled under the united nations psychotropic drug conventions, psilocybin and mdma, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. |
2024-05-19 |
2024-05-27 |
Not clear |
| Val Bellma. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon. Cancers. vol 16. issue 9. 2024-05-13. PMID:38730654. |
review of psilocybin use for depression among cancer patients after approval in oregon. |
2024-05-13 |
2024-05-27 |
Not clear |
| Val Bellma. Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon. Cancers. vol 16. issue 9. 2024-05-13. PMID:38730654. |
despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through oregon's measure 109 in 2020, significant challenges have impeded its implementation. |
2024-05-13 |
2024-05-27 |
Not clear |
| EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ (Clinical research ed.). vol 385. 2024-05-04. PMID:38704154. |
expression of concern: efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. |
2024-05-04 |
2024-05-07 |
Not clear |
| Claire Parker, Bethany Marie Woo. At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse. Social work. 2024-05-02. PMID:38697188. |
at the forefront: social workers' role in psilocybin treatment for depression and substance misuse. |
2024-05-02 |
2024-05-05 |
Not clear |
| Riccardo De Giorgi, Roger Ed. Psilocybin for depression. BMJ (Clinical research ed.). vol 385. 2024-05-01. PMID:38692675. |
psilocybin for depression. |
2024-05-01 |
2024-05-04 |
Not clear |
| Athina-Marina Metaxa, Mike Clark. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ (Clinical research ed.). vol 385. 2024-05-01. PMID:38692686. |
efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. |
2024-05-01 |
2024-05-04 |
Not clear |